ADAM10 Plasma and CSF Levels Are Increased in Mild Alzheimer’s Disease

• Main Authors: Izabela Pereira Vanatabe, Rafaela Peron, Marina Mantellatto Grigoli, Silvia Pelucchi, Giulia De Cesare, Thamires Magalhães, Patricia Regina Manzine, Marcio Luiz Figueredo Balthazar, Monica Di Luca, Elena Marcello, Marcia Regina Cominetti
• Format: Article
• Language: English
• Published: MDPI AG 2021-02-01
• Series: International Journal of Molecular Sciences
• Subjects: ADAM10; biomarker; Alzheimer’s disease
• Online Access: https://www.mdpi.com/1422-0067/22/5/2416

ADAM10 is the main α-secretase that participates in the non-amyloidogenic cleavage of amyloid precursor protein (APP) in neurons, inhibiting the production of β-amyloid peptide (Aβ) in Alzheimer’s disease (AD). Strong recent evidence indicates the importance of the localization of ADAM10 for its activity as a protease. In this study, we investigated ADAM10 activity in plasma and CSF samples of patients with amnestic mild cognitive impairment (aMCI) and mild AD compared with cognitively healthy controls. Our results indicated that plasma levels of soluble ADAM10 were significantly increased in the mild AD group, and that in these samples the protease was inactive, as determined by activity assays. The same results were observed in CSF samples, indicating that the increased plasma ADAM10 levels reflect the levels found in the central nervous system. In SH-SY5Y neuroblastoma cells, ADAM10 achieves its major protease activity in the fraction obtained from plasma membrane lysis, where the mature form of the enzyme is detected, confirming the importance of ADAM10 localization for its activity. Taken together, our results demonstrate the potential of plasma ADAM10 to act as a biomarker for AD, highlighting its advantages as a less invasive, easier, faster, and lower-cost processing procedure, compared to existing biomarkers.